search
Back to results

Efficacy and Safety Evaluation of PC-SOD for Injection in Reducing Myocardial Reperfusion Injury

Primary Purpose

Myocardial Reperfusion Injury

Status
Unknown status
Phase
Phase 2
Locations
China
Study Type
Interventional
Intervention
PC-SOD
placebo
Sponsored by
Beijing Tide Pharmaceutical Co., Ltd
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Myocardial Reperfusion Injury

Eligibility Criteria

18 Years - 75 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Age 18 - 75 years, male or female;
  2. Meeting the diagnostic criteria of AMI (chest pain for over 10 - 20 min, which could not be relieved completely by oral nitroglycerin; ST elevation ≥ 2 mm in two or more adjacent leads in leads V1-V5 );
  3. Killip classes I or II;
  4. Coronary angiography possible within 6 hours of onset;
  5. Emergent coronary angiography showing occlusion in left anterior descending artery (TIMI grade 0 - 1); patients with this symptom could also be included despite inconformity to criterion 2);
  6. Willingness to participate in the trial with ethical approval and informed consent provision.

Exclusion Criteria:

General exclusion criteria

  1. Previous history of myocardial infarction;
  2. History of myocardial revascularization before screening;
  3. Thrombolytic treatment after onset;
  4. Cardiogenic shock;
  5. Cardiopulmonary resuscitation between onset and screening;
  6. Atrial fibrillation, atrioventricular block (degree I, II or III), and other severe arrhythmias that cannot be corrected and affect hemodynamics;
  7. Suspected of aortic dissection;
  8. Diabetes with long-term insulin use, or definite macrovascular or small vascular lesions (stroke, diabetic nephropathy, retinopathy, diabetic foot, and etc.);
  9. History of major surgeries within 6 months;
  10. History of stroke within 6 months;
  11. History of immune disorders within 6 months (such as cancer, lymphoma, HIV or hepatitis), or use of immunosuppressive agents at doses that can cause immunosuppression within 10 days;
  12. Clinically significant diseases of the respiratory, digestive, blood, immune, endocrine, nervous or urinary systems (renal insufficiency in particular), and diseases that might cause serious risk to patients based on the judgement of researchers;
  13. Allergy to two or more drugs and/or foods, or known allergy to sucrose;
  14. Any contraindications for cardiac MRI, such as implantation of metal objects (pacemakers and/or implantable defibrillators; insulin pumps, or any other electronic devices; cerebral clips, aneurysm clips, and etc.), and other contraindications (such as claustrophobia);
  15. Pregnancy or lactation in women;
  16. Participation in other clinical trials within 3 months;
  17. Situations considered unsuitable for enrollment (such as disease condition or patient compliance).

Exclusion criteria for angiography

  1. Occlusion of left main artery;
  2. Apart from the left anterior descending branch, other blood vessels requiring revascularization in the same period or within a month.

Sites / Locations

  • Wuhan Asia Heart Hospital
  • Zhongshan HospitalRecruiting

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm Type

Experimental

Experimental

Experimental

Placebo Comparator

Arm Label

40 mg treatment group

80 mg treatment group

160 mg treatment group

placebo control group

Arm Description

PC-SOD 40 mg dissolved in 10 mL of 5% glucose injection and intravenously administrated before recanalization.

PC-SOD 80 mg dissolved in 10 mL of 5% glucose injection and intravenously administrated before recanalization.

PC-SOD 160 mg dissolved in 10 mL of 5% glucose injection and intravenously administrated before recanalization.

placebo dissolved in 10 mL of 5% glucose injection and intravenously administrated before recanalization.

Outcomes

Primary Outcome Measures

The myocardial salvage index at 7 d after PCI
The myocardial salvage index is defined as (area of myocardial edema - area of myocardial infarction)/area of myocardial edema.
The area of myocardial infarction at 7 d after PCI (detected by delayed-enhanced MRI [Magnetic Resonance Imaging] )
The area of myocardial infarction is defined as the percentage of left ventricular myocardium occupied by delayed enhancement.
Area of microvascular occlusion at 7 d after PCI
Microvascular occlusion is defined as the area with no enhancement in the infarcted regions where delayed enhancement can be observed on MRI scans.
The area of infarction determined by the AUC (area under curve) for CK-MB (creatine kinase-muscle/brain) at 72h after PCI.
The area of infarction at 72h after surgery will be roughly estimated by calculating the AUC for CK-MB (before operation, and at 6, 12, 24, 48 and 72h after operation, respectively).
Cardiac function at 7 d after PCI
Cardiac function is assessed by assessing the left ventricular ejection fraction (percentage of stroke output to end-diastolic volume).
The TIMI (thrombolysis in myocardial infarction) grade of coronary blood flow after PCI.
Coronary artery reperfusion will be assessed by the TIMI grading system, whose grades include: Grade 0: no contrast filling at the occlusion site and distal end; Grade 1: the contrast passes some of the occluded sites, but cannot fill the distal vessels; Grade 2: the contrast can fill the distal end of coronary artery completely, but the filling and clearing of contrast is slower than that of normal coronary artery; Grade 3: the contrast can fill the distal end rapidly and completely, and can be removed quickly. The TIMI flow grades will be determined by two physicians separately. In case of disagreement, a lead physician will help make the final call.
The corrected TIMI frame count (cTFC) after PCI.
The left anterior descending (LAD) artery will be analyzed in a 30º right anterior oblique view with 30º cranial angulation. The left circumflex (LCX) will be analyzed in a 30º right anterior oblique view with 30º caudal angulation. The right coronary artery (RCA) will be analyzed in a 45º left anterior oblique view.
TIMI myocardial perfusion grade (TMPG) after PCI
Grade 0: no contrast entering the myocardium; Grade 1: the contrast enters myocardium slowly, with myocardial staining not disappearing or lasting for more than 30 s in the targeted vessels; Grade 2: delayed entering and disappearing of contrast in the myocardium, exceeding 3 cardiac cycles; Grade 3: normal entering and disappearing of contrast in the myocardium, occurring within 3 cardiac cycles.
Percentage of ST-segment resolution on ECG (electrocardiogram) at 90 min after PCI
ST-resolution is defined as more than 50% of resolution.
Number of cardiovascular events within 30 d after PCI
Cardiovascular events included all-cause death, cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, and hospitalization due to heart failure.
SOD (Superoxide Dismutase) activity
Change from Baseline SOD activity at 6h, 12h, 24h, 48h, 72h and 7 d after surgery.
Occurence of adverse events
Occurence of adverse events
Cardiac function at 30 d after PCI
Cardiac function is assessed by assessing the left ventricular ejection fraction (percentage of stroke output to end-diastolic volume).

Secondary Outcome Measures

Full Information

First Posted
June 5, 2019
Last Updated
September 24, 2019
Sponsor
Beijing Tide Pharmaceutical Co., Ltd
Collaborators
Peking University First Hospital
search

1. Study Identification

Unique Protocol Identification Number
NCT03995732
Brief Title
Efficacy and Safety Evaluation of PC-SOD for Injection in Reducing Myocardial Reperfusion Injury
Official Title
Efficacy and Safety Evaluation of Phosphatidyl Choline Cu/Zn Superoxide Dismutase (PC-SOD) for Injection in Reducing Myocardial Reperfusion Injury: a Multicenter, Randomized, Single-blind, Placebo-controlled Dose-finding Study
Study Type
Interventional

2. Study Status

Record Verification Date
September 2019
Overall Recruitment Status
Unknown status
Study Start Date
June 18, 2019 (Actual)
Primary Completion Date
October 31, 2020 (Anticipated)
Study Completion Date
March 30, 2021 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Beijing Tide Pharmaceutical Co., Ltd
Collaborators
Peking University First Hospital

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No

5. Study Description

Brief Summary
The current study aims to evaluate different doses of PC-SOD injections for efficacy and safety in comparison to placebo, in order to provide a basis for future clinical trials in terms of experimental design and dose selection.
Detailed Description
The study is a randomized, single-blind, multi-center, placebo-controlled trial to preliminarily evaluate the efficacy and safety of PC-SOD, and to provide a basis for dose selection in the next stage of study. For each participant, the trial will be divided into the screening/treatment (screening and treatment conducted during the first visit, 0 d) and safety follow-up (1 - 30 d) stages. The study will screen 120 eligible subjects. After successful screening, the subjects will be randomly assigned into four groups of equal size, including the 40 mg PC-SOD, 80 mg PC-SOD, 160 mg PC-SOD and placebo control groups. Subjects in each group will be administered the corresponding intervention, followed by PCI treatment. During the safety follow-up stage, the subjects will receive basic treatment based on Guidelines for Management of Patients with ST-segment elevation myocardial infarction. Treatments will include dual anti-platelet therapy, beta-blockers, ACEI/ARB (angiotensin-converting enzyme inhibitor/ angiotensin receptor blocker), statins, anticoagulants, and so on. By comparing the efficacy and safety endpoints of patients in the experimental and placebo control groups, the study aims to preliminarily evaluate the efficacy and safety of different doses of PC-SOD in reducing myocardial reperfusion injury.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Myocardial Reperfusion Injury

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
Participant
Masking Description
Since the appearance of PC-SOD preparations cannot be identical to that of placebo, and treatment groups have different administration doses, the study will be conducted in a single-blind manner, where only subjects (and families) are blinded and do not know whether they are treated by PC-SOD or placebo before unblinding. Interpretation of cardiac MRI and ECG will also be conducted in a blinding manner. Images of all subjects will be evaluated blindly by researchers not directly involved in the study.
Allocation
Randomized
Enrollment
120 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
40 mg treatment group
Arm Type
Experimental
Arm Description
PC-SOD 40 mg dissolved in 10 mL of 5% glucose injection and intravenously administrated before recanalization.
Arm Title
80 mg treatment group
Arm Type
Experimental
Arm Description
PC-SOD 80 mg dissolved in 10 mL of 5% glucose injection and intravenously administrated before recanalization.
Arm Title
160 mg treatment group
Arm Type
Experimental
Arm Description
PC-SOD 160 mg dissolved in 10 mL of 5% glucose injection and intravenously administrated before recanalization.
Arm Title
placebo control group
Arm Type
Placebo Comparator
Arm Description
placebo dissolved in 10 mL of 5% glucose injection and intravenously administrated before recanalization.
Intervention Type
Drug
Intervention Name(s)
PC-SOD
Intervention Description
PC-SOD will be dissolved in 10 mL of 5% glucose injection and intravenously administrated before recanalization.
Intervention Type
Drug
Intervention Name(s)
placebo
Intervention Description
Placebo will be dissolved in 10 mL of 5% glucose injection and intravenously administrated before recanalization.
Primary Outcome Measure Information:
Title
The myocardial salvage index at 7 d after PCI
Description
The myocardial salvage index is defined as (area of myocardial edema - area of myocardial infarction)/area of myocardial edema.
Time Frame
7 days
Title
The area of myocardial infarction at 7 d after PCI (detected by delayed-enhanced MRI [Magnetic Resonance Imaging] )
Description
The area of myocardial infarction is defined as the percentage of left ventricular myocardium occupied by delayed enhancement.
Time Frame
7 days
Title
Area of microvascular occlusion at 7 d after PCI
Description
Microvascular occlusion is defined as the area with no enhancement in the infarcted regions where delayed enhancement can be observed on MRI scans.
Time Frame
7 days
Title
The area of infarction determined by the AUC (area under curve) for CK-MB (creatine kinase-muscle/brain) at 72h after PCI.
Description
The area of infarction at 72h after surgery will be roughly estimated by calculating the AUC for CK-MB (before operation, and at 6, 12, 24, 48 and 72h after operation, respectively).
Time Frame
72 hours
Title
Cardiac function at 7 d after PCI
Description
Cardiac function is assessed by assessing the left ventricular ejection fraction (percentage of stroke output to end-diastolic volume).
Time Frame
7 days
Title
The TIMI (thrombolysis in myocardial infarction) grade of coronary blood flow after PCI.
Description
Coronary artery reperfusion will be assessed by the TIMI grading system, whose grades include: Grade 0: no contrast filling at the occlusion site and distal end; Grade 1: the contrast passes some of the occluded sites, but cannot fill the distal vessels; Grade 2: the contrast can fill the distal end of coronary artery completely, but the filling and clearing of contrast is slower than that of normal coronary artery; Grade 3: the contrast can fill the distal end rapidly and completely, and can be removed quickly. The TIMI flow grades will be determined by two physicians separately. In case of disagreement, a lead physician will help make the final call.
Time Frame
within 24 hours
Title
The corrected TIMI frame count (cTFC) after PCI.
Description
The left anterior descending (LAD) artery will be analyzed in a 30º right anterior oblique view with 30º cranial angulation. The left circumflex (LCX) will be analyzed in a 30º right anterior oblique view with 30º caudal angulation. The right coronary artery (RCA) will be analyzed in a 45º left anterior oblique view.
Time Frame
within 24 hours
Title
TIMI myocardial perfusion grade (TMPG) after PCI
Description
Grade 0: no contrast entering the myocardium; Grade 1: the contrast enters myocardium slowly, with myocardial staining not disappearing or lasting for more than 30 s in the targeted vessels; Grade 2: delayed entering and disappearing of contrast in the myocardium, exceeding 3 cardiac cycles; Grade 3: normal entering and disappearing of contrast in the myocardium, occurring within 3 cardiac cycles.
Time Frame
within 24 hours
Title
Percentage of ST-segment resolution on ECG (electrocardiogram) at 90 min after PCI
Description
ST-resolution is defined as more than 50% of resolution.
Time Frame
90 minutes
Title
Number of cardiovascular events within 30 d after PCI
Description
Cardiovascular events included all-cause death, cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, and hospitalization due to heart failure.
Time Frame
30 days
Title
SOD (Superoxide Dismutase) activity
Description
Change from Baseline SOD activity at 6h, 12h, 24h, 48h, 72h and 7 d after surgery.
Time Frame
0 hours, 6 hours, 12 hours, 24 hours, 48 hours, 72 hours and 7 days after surgery
Title
Occurence of adverse events
Description
Occurence of adverse events
Time Frame
During patient hospitalization, up to 30 days
Title
Cardiac function at 30 d after PCI
Description
Cardiac function is assessed by assessing the left ventricular ejection fraction (percentage of stroke output to end-diastolic volume).
Time Frame
30 days

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Age 18 - 75 years, male or female; Meeting the diagnostic criteria of AMI (chest pain for over 10 - 20 min, which could not be relieved completely by oral nitroglycerin; ST elevation ≥ 2 mm in two or more adjacent leads in leads V1-V5 ); Killip classes I or II; Coronary angiography possible within 6 hours of onset; Emergent coronary angiography showing occlusion in left anterior descending artery (TIMI grade 0 - 1); patients with this symptom could also be included despite inconformity to criterion 2); Willingness to participate in the trial with ethical approval and informed consent provision. Exclusion Criteria: General exclusion criteria Previous history of myocardial infarction; History of myocardial revascularization before screening; Thrombolytic treatment after onset; Cardiogenic shock; Cardiopulmonary resuscitation between onset and screening; Atrial fibrillation, atrioventricular block (degree I, II or III), and other severe arrhythmias that cannot be corrected and affect hemodynamics; Suspected of aortic dissection; Diabetes with long-term insulin use, or definite macrovascular or small vascular lesions (stroke, diabetic nephropathy, retinopathy, diabetic foot, and etc.); History of major surgeries within 6 months; History of stroke within 6 months; History of immune disorders within 6 months (such as cancer, lymphoma, HIV or hepatitis), or use of immunosuppressive agents at doses that can cause immunosuppression within 10 days; Clinically significant diseases of the respiratory, digestive, blood, immune, endocrine, nervous or urinary systems (renal insufficiency in particular), and diseases that might cause serious risk to patients based on the judgement of researchers; Allergy to two or more drugs and/or foods, or known allergy to sucrose; Any contraindications for cardiac MRI, such as implantation of metal objects (pacemakers and/or implantable defibrillators; insulin pumps, or any other electronic devices; cerebral clips, aneurysm clips, and etc.), and other contraindications (such as claustrophobia); Pregnancy or lactation in women; Participation in other clinical trials within 3 months; Situations considered unsuitable for enrollment (such as disease condition or patient compliance). Exclusion criteria for angiography Occlusion of left main artery; Apart from the left anterior descending branch, other blood vessels requiring revascularization in the same period or within a month.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Huo Yong, master
Phone
13901333060
Email
drhuoyong@163.com
Facility Information:
Facility Name
Wuhan Asia Heart Hospital
City
Wuhan
State/Province
Hubei
ZIP/Postal Code
430022
Country
China
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Su Xi, MD
Facility Name
Zhongshan Hospital
City
Shanghai
State/Province
Shanghai
ZIP/Postal Code
200032
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Ge Junbo, MD
Email
ge.junbo@zs-hospital.sh.cn

12. IPD Sharing Statement

Plan to Share IPD
Undecided
Citations:
PubMed Identifier
17855673
Citation
Yellon DM, Hausenloy DJ. Myocardial reperfusion injury. N Engl J Med. 2007 Sep 13;357(11):1121-35. doi: 10.1056/NEJMra071667. No abstract available.
Results Reference
background
PubMed Identifier
2826476
Citation
Zweier JL. Measurement of superoxide-derived free radicals in the reperfused heart. Evidence for a free radical mechanism of reperfusion injury. J Biol Chem. 1988 Jan 25;263(3):1353-7.
Results Reference
background
PubMed Identifier
2185587
Citation
Werns SW, Lucchesi BR. Free radicals and ischemic tissue injury. Trends Pharmacol Sci. 1990 Apr;11(4):161-6. doi: 10.1016/0165-6147(90)90068-J.
Results Reference
background
PubMed Identifier
2553296
Citation
Kloner RA, Przyklenk K, Whittaker P. Deleterious effects of oxygen radicals in ischemia/reperfusion. Resolved and unresolved issues. Circulation. 1989 Nov;80(5):1115-27. doi: 10.1161/01.cir.80.5.1115.
Results Reference
background
PubMed Identifier
3943152
Citation
Przyklenk K, Kloner RA. Superoxide dismutase plus catalase improve contractile function in the canine model of the "stunned myocardium". Circ Res. 1986 Jan;58(1):148-56. doi: 10.1161/01.res.58.1.148.
Results Reference
background
PubMed Identifier
2653661
Citation
Engler R, Gilpin E. Can superoxide dismutase alter myocardial infarct size? Circulation. 1989 May;79(5):1137-42. doi: 10.1161/01.cir.79.5.1137. No abstract available.
Results Reference
background
PubMed Identifier
7996483
Citation
Igarashi R, Hoshino J, Ochiai A, Morizawa Y, Mizushima Y. Lecithinized superoxide dismutase enhances its pharmacologic potency by increasing its cell membrane affinity. J Pharmacol Exp Ther. 1994 Dec;271(3):1672-7.
Results Reference
background
PubMed Identifier
18070953
Citation
Wu E, Ortiz JT, Tejedor P, Lee DC, Bucciarelli-Ducci C, Kansal P, Carr JC, Holly TA, Lloyd-Jones D, Klocke FJ, Bonow RO. Infarct size by contrast enhanced cardiac magnetic resonance is a stronger predictor of outcomes than left ventricular ejection fraction or end-systolic volume index: prospective cohort study. Heart. 2008 Jun;94(6):730-6. doi: 10.1136/hrt.2007.122622. Epub 2007 Dec 10.
Results Reference
background

Learn more about this trial

Efficacy and Safety Evaluation of PC-SOD for Injection in Reducing Myocardial Reperfusion Injury

We'll reach out to this number within 24 hrs